Ignet

Gene Information

Gene symbol: IGHJ2

Gene name: immunoglobulin heavy joining 2

HGNC ID: 5534

Related Genes

#	Gene Symbol	Number of hits
1	BCL2	1 hits
2	IGHJ1	1 hits
3	IGL	1 hits
4	SP2	1 hits

Related Sentences

#	PMID	Sentence
1	8432980	Four mAb utilized JH4, two JH6, two JH3, and one JH5; no mAb utilized JH1 or JH2 genes.
2	10975396	Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
3	10975396	The majority of follicular lymphoma patients carry a t(14,18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH).
4	10975396	We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker.
5	10975396	Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer.
6	10975396	Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum.
7	10975396	Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
8	10975396	The majority of follicular lymphoma patients carry a t(14,18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH).
9	10975396	We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker.
10	10975396	Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer.
11	10975396	Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum.
12	10975396	Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
13	10975396	The majority of follicular lymphoma patients carry a t(14,18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH).
14	10975396	We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker.
15	10975396	Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer.
16	10975396	Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum.
17	10975396	Serum BCL2/IGH DNA in follicular lymphoma patients: a minimal residual disease marker.
18	10975396	The majority of follicular lymphoma patients carry a t(14,18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH).
19	10975396	We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker.
20	10975396	Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer.
21	10975396	Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum.
22	11398807	The Vh gene (36-60), the D gene (Sp2), and the J gene (Jh2) encoding the heavy chain variable regions of all six mAbs, were similar and showed a high homology in the nucleotide sequence.
23	15569635	This technology utilizes specific peptides which bind to CD4, CD8 or other proteins on the surface of T cells (T cell binding ligand (TCBL)), macrophage and dendritic cells (immune cell binding ligand (ICBL)) to promote the immunogenicity of an epitope, activate T cell and other protective responses, and direct the immune response to either a Th1 or a Th2 type of response.
24	15569635	The J TCBL/ICBL is a peptide from beta-2-microglobulin which binds to the CD8 protein and promotes Th1 responses and the G TCBL/ICBL is a peptide from the beta chain of MHC II molecules that binds to the CD4 protein and promotes Th2 responses.
25	15569635	The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge.
26	15569635	Initiation of the immune response by the JgD vaccine was dependent on functional CD4, CD8 expressing cells and interferon gamma and delivery of protection was dependent upon CD4 and interferon gamma.
27	19744999	Typically, IGs are composed of two identical heavy chains (IGH) and two identical light chains (IGL).